Gene therapy trial for bladder control after spinal cord injury
Part of Brain & nervous system, Injuries & trauma clinical trials.
This trial tests a new gene therapy called EG110A for people with overactive bladders due to spinal cord injury. It aims to reduce urinary incontinence and may offer an option if other treatments haven't worked well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a spinal cord injury at least 12 months ago that is stable and above the lower back.
- You have urinary incontinence due to an overactive bladder that has been confirmed by a bladder test.
- You have tried medication for overactive bladder for at least 3 months and still have at least 8 leaks per week, or you have had an inadequate response to Botox injections.
- You are willing not to get surgery for bladder control during the study.
- You do not have an active herpes infection near your mouth or genitals, and no recent cancer treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a spinal cord stimulator to help improve bladder and pelvic function in people with a spinal cord injury. You would use a small device placed near the spine that sends electrical pulses to help control your bladder better.
This trial tests if giving Botox injections early (within 20 weeks of injury) into the bladder muscle can help with bladder function and prevent problems. It may help people with recent, severe spinal cord injuries above the T6 level.
This study tests a non-invasive treatment called transcutaneous tibial nerve stimulation (TTNS) for people with overactive bladder caused by a spinal cord injury. The treatment involves applying mild electrical pulses to the ankle to help improve bladder control. If you qualify, you will receive the treatment and be monitored for safety and effectiveness.
This study tests how well and how safely vibegron works long-term in children (ages 2 to under 18) with a nerve-related bladder condition, who regularly use intermittent catheterization. It also tracks how the body processes the medicine and whether it helps bladder control over time.
This study follows up on people who previously received EG110A gene therapy in an earlier trial (EG110A-001-01) to monitor their health over a longer period. It helps doctors understand the lasting safety and effects of the treatment.
This trial tests a nerve-stimulation approach to improve bladder control in people with spinal cord injury. It specifically targets bladder problems that require clean intermittent catheter use and includes regular testing over 6 months.
Hear when a new Neurogenic Detrusor Overactivity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.